EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Incidence, Mortality, and Potential Prognostic Features of Immune Checkpoint Inhibitor-Associated Myocarditis: A Systematic Review and Meta-Analysis

Faiz Shaikh, Matheus Hissa Lourenço Ferreira, Roshan Ananda, Shaz Raja, Débora Regina de Aguiar, Amresh Gul, Angie Carolina Benitez Román, Kabir Khatiwada, Riddhi Solanki, Samara Oliveira Mattoso, Zahid Khan

SN Comprehensive Clinical Medicine · 29.09.2026 · 8 (1)

DOI: 10.1007/s42399-026-02702-3 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 29.09.2026. Verfasst von Faiz Shaikh und 10 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors improve outcomes in several cancers but can cause immune-related adverse events. ICI-associated myocarditis is uncommon and potentially fatal. This review summarizes evidence on its incidence, features, morbidity, mortality, and management in adults with cancer. Main Body We searched PubMed, EMBASE, Scopus, Web of Science, and the Cochrane Library to January 2026 (PROSPERO CRD42024547168; PRISMA). Ten observational studies were included. Four studies (11,164 ICI-exposed patients) gave a pooled incidence of 1.93% (95% CI 1.42–2.63; prediction interval 1.39–2.68). Three studies (191 myocarditis cases) gave a pooled short-term/as-reported mortality of 22.1% (95% CI 6.8–52.5; prediction interval 4.3–64.4). The wide interval reflects few studies and non-uniform follow-up. Overlap events, especially myositis, were often described. High-dose corticosteroids were the main treatment. Diagnostic criteria varied.

Conclusion

ICI-associated myocarditis is uncommon but can be fatal. Mortality estimates are imprecise. Severity and overlap syndromes are potential prognostic features from individual studies, not a pooled analysis. Standardized criteria and prospective cohorts are needed.

Zitieren

APA

Shaikh, F., Ferreira, M. H. L., Ananda, R., Raja, S., Aguiar, D. R. D., Gul, A., Román, A. C. B., Khatiwada, K., Solanki, R., Mattoso, S. O., & Khan, Z. (2026). Incidence, Mortality, and Potential Prognostic Features of Immune Checkpoint Inhibitor-Associated Myocarditis: A Systematic Review and Meta-Analysis. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02702-3

Vancouver

Shaikh F, Ferreira MHL, Ananda R, Raja S, Aguiar DRD, Gul A, et al. Incidence, Mortality, and Potential Prognostic Features of Immune Checkpoint Inhibitor-Associated Myocarditis: A Systematic Review and Meta-Analysis. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02702-3

BibTeX
@article{Shaikh2026,
  author = {Shaikh, Faiz and Ferreira, Matheus Hissa Lourenço and Ananda, Roshan and Raja, Shaz and Aguiar, Débora Regina de and Gul, Amresh and Román, Angie Carolina Benitez and Khatiwada, Kabir and Solanki, Riddhi and Mattoso, Samara Oliveira and Khan, Zahid},
  title = {Incidence, Mortality, and Potential Prognostic Features of Immune Checkpoint Inhibitor-Associated Myocarditis: A Systematic Review and Meta-Analysis},
  journal = {SN Comprehensive Clinical Medicine},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.1007/s42399-026-02702-3}
}
Kostenlos starten →